Morgan Stanley Ocular Therapeutix, Inc Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Morgan Stanley holds 2,465,676 shares of OCUL stock, worth $28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,465,676

Previous 2,571,723 4.12%

Holding current value

$28 Million

Previous $23.9 Million 20.78%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$9.09 - $13.6 $963,967 - $1.44 Million	-106,047 Reduced 4.12%	2,465,676 $28.8 Million
Q2 2025 Aug 15, 2025	BUY	$6.02 - $9.46 $2.31 Million - $3.63 Million	383,245 Added 17.51%	2,571,723 $23.9 Million
Q1 2025 May 15, 2025	BUY	$5.93 - $9.08 $2.17 Million - $3.32 Million	365,553 Added 20.05%	2,188,478 $16 Million
Q4 2024 Feb 14, 2025	BUY	$8.33 - $11.47 $1.99 Million - $2.74 Million	238,750 Added 15.07%	1,822,925 $15.6 Million
Q3 2024 May 14, 2025	BUY	$6.45 - $9.23 $2.72 Million - $3.89 Million	421,694 Added 36.28%	1,584,175 $13.8 Million

Q3 2024 Nov 14, 2024	BUY	$6.45 - $9.23 $2.72 Million - $3.89 Million	421,694 Added 36.28%	1,584,175 $13.8 Million
Q2 2024 May 14, 2025	SELL	$4.2 - $8.69 $2.77 Million - $5.74 Million	-660,444 Reduced 36.23%	1,162,481 $7.95 Million
Q2 2024 Oct 17, 2024	SELL	$4.2 - $8.69 $884,326 - $1.83 Million	-210,554 Reduced 15.33%	1,162,481 $7.95 Million
Q2 2024 Aug 14, 2024	SELL	$4.2 - $8.69 $884,326 - $1.83 Million	-210,554 Reduced 15.33%	1,162,481 $7.95 Million
Q1 2024 Oct 17, 2024	BUY	$3.85 - $10.93 $810,632 - $2.3 Million	210,554 Added 18.11%	1,373,035 $12.5 Million
Q1 2024 Aug 16, 2024	BUY	$3.85 - $10.93 $4.04 Million - $11.5 Million	1,049,880 Added 324.88%	1,373,035 $12.5 Million
Q1 2024 May 15, 2024	BUY	$3.85 - $10.93 $4.04 Million - $11.5 Million	1,049,880 Added 324.88%	1,373,035 $12.5 Million
Q4 2023 Aug 16, 2024	SELL	$2.08 - $4.52 $1.75 Million - $3.79 Million	-839,326 Reduced 72.2%	323,155 $1.44 Million
Q4 2023 Feb 13, 2024	BUY	$2.08 - $4.52 $159,598 - $346,819	76,730 Added 31.14%	323,155 $1.44 Million
Q3 2023 Nov 15, 2023	BUY	$3.14 - $5.04 $42,892 - $68,846	13,660 Added 5.87%	246,425 $773,000
Q2 2023 Aug 14, 2023	SELL	$4.6 - $7.64 $4.37 Million - $7.25 Million	-948,938 Reduced 80.3%	232,765 $1.2 Million
Q1 2023 May 15, 2023	BUY	$2.79 - $6.27 $2.1 Million - $4.73 Million	753,831 Added 176.18%	1,181,703 $6.23 Million
Q4 2022 Feb 14, 2023	BUY	$2.61 - $4.41 $625,248 - $1.06 Million	239,559 Added 127.21%	427,872 $1.2 Million
Q3 2022 Nov 14, 2022	SELL	$4.09 - $6.5 $166,986 - $265,382	-40,828 Reduced 17.82%	188,313 $782,000
Q2 2022 Oct 27, 2022	BUY	$3.01 - $5.22 $22,514 - $39,045	7,480 Added 3.37%	229,141 $920,000
Q2 2022 Aug 15, 2022	BUY	$3.01 - $5.22 $22,514 - $39,045	7,480 Added 3.37%	229,141 $920,000
Q1 2022 Oct 27, 2022	SELL	$4.83 - $7.35 $36,128 - $54,978	-7,480 Reduced 3.26%	221,661 $1.1 Million
Q1 2022 May 13, 2022	SELL	$4.83 - $7.35 $969,434 - $1.48 Million	-200,711 Reduced 47.52%	221,661 $1.1 Million
Q4 2021 Feb 14, 2022	SELL	$6.16 - $12.07 $1.39 Million - $2.73 Million	-226,443 Reduced 34.9%	422,372 $2.94 Million
Q3 2021 Nov 15, 2021	BUY	$9.7 - $14.34 $6.29 Million - $9.3 Million	648,815 New	648,815 $6.49 Million

Others Institutions Holding OCUL

# of Institutions

235

Shares Held

157M

Call Options Held

1.24M

Put Options Held

423K

View Full List

About OCULAR THERAPEUTIX, INC

Ticker OCUL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,966,896
Market Cap $875M
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...

More about OCUL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account